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Coxsackieviruses B (CVB) (B1–B6), positive-strand RNA viruses, cause a variety of diseases. CVB4 may have a causal role
in insulin-dependent diabetes mellitus. IFN-a inhibits CVB replication; however, the mechanism is not well known. The
interferon-a-inducible human MxA protein exerts an antiviral activity against negative-strand RNA viruses and against Semliki
Forest virus, a positive-strand RNA virus. To test the antiviral spectrum of MxA against CVB4, we took advantage of stably
transfected Vero cells expressing MxA (Vero/MxA) in 98% of cells. Compared with control cells, in Vero/MxA cells, CVB4
yields were dramatically reduced and expression of the VP1 CVB protein analyzed by immunofluorescence was highly
restricted. Furthermore, the accumulation of positive- and negative-strand CVB4 RNA was prevented as shown by in situ
hybridization and RT-PCR. These results indicate that the antiviral activity of MxA extends to CVB4 and that its replication
cycle is inhibited at an early step in Vero/MxA cells. © 2001 Academic PressKey Words: IFN-a; MxA; transfected cells; enterovirus; coxsackievirus B4; Vero cells; 29–59 OAS; immunochemilumines-
cence; in situ hybridization; RT-PCR; immunofluorescence.
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aINTRODUCTION
Coxsackieviruses B1–B6 (CVB), members of the en-
terovirus group in the Picornaviridae family, are nonen-
veloped viruses. Their genome is a single positive-strand
RNA, contained in a capsid composed of 60 protomers,
each consisting of one copy of the viral proteins VP1,
VP2, VP3, and VP4. The viruses enter the cell via cellular
receptors (Bergelson et al., 1997; De Verdugo et al., 1995;
Shafren et al., 1995). The mechanism of uncoating is not
well known; into the cell, viral RNA associates with ribo-
somes. The viral genome serves as mRNA for the syn-
thesis of a polyprotein precursor cleaved to yield the viral
proteins. The positive-strand RNA is copied into negative
strands which in turn serve as templates for the synthe-
sis of positive-strand genomic RNAs or are translated in
proteins. Structural proteins such as VP1, formed by
cleavage of the precursor polyprotein, associate with
positive-strand RNA to form virions that free themselves
from the cells by cell lysis (Rueckert et al., 1996).
Coxsackieviruses B are highly prevalent human patho-
gens associated with a variety of acute diseases (myo-
carditis, meningoencephalitis, Bornholm disease, her-
pangina, etc.) (Melnick, 1996). Studies indicate that CVB3
and CVB4 may have a causal role in chronic diseases
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84such as chronic myocarditis and insulin-dependent type
1 diabetes (Kandolf et al., 1993; Graves et al., 1997).
Increased levels of IFN-a in plasma have been associ-
ated with CVB infection, and IFN-a mRNA has been
etected in the blood cells of individuals with EV RNA in
heir blood (Chehadeh et al., 2000a; Dommergues et al.,
994). IFN-a is known to play an important role in primary
efense against viral infections. Following treatment with
FN-a, CVB infection is impaired in mice (Matsumori et
l., 1988) and IFN-a can inhibit CVB replication in cul-
tured cells (Heim et al., 1995, 1997).
IFN-a and -b exert pleiotropic effects on cells by in-
teraction with a cell-surface receptor. Then, the IFN-a
antiviral activity is mediated, in part, by inducing intra-
cellular proteins, such as 29–59 oligoadenylate syn-
thetase (29–59 OAS), a 68-kDa protein kinase (PKR), or
MxA protein (for review, see Taylor and Grossberg, 1990).
Human MxA, a 78-kDa protein induced specifically by
IFN-a and IFN-b but not by other cytokines, accumulates
in the cytoplasm (Horisberger and Hochkepel, 1987; Si-
mon et al., 1991). The MxA is a GTPase, and the loss of
GTP binding due to mutations in the GTP-binding ele-
ment of MxA is accompanied by a loss of antiviral activity
(Ponten et al., 1997; Pitossi et al., 1993).
MxA protein inhibits the multiplication of negative-
strand RNA viruses such as influenza virus, vesicular
stomatitus virus (VSV), measles virus, or other viruses
belonging to the family Bunyaviridae (Pavlovic et al.,
1990, 1992; Schneider-Schaulies et al., 1994; Schnorr et
al., 1993; Frese et al., 1995, 1996). Moreover, it has been
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85MxA PROTEIN AND COXSACKIEVIRUS B4reported that MxA-transfected cells were protected
against Semliki Forest virus (SFV), a togavirus with a
single-stranded RNA genome of positive polarity,
whereas they were not protected against the multiplica-
tion of other positive-stranded RNA virus, mengovirus,
and encephalomyocarditis virus belonging to the Picor-
naviridae family and against the multiplication of a DNA
virus, herpes simplex virus type 1 (Pavlovic et al., 1990;
Landis et al., 1998).
It has been reported that 29–59 OAS-transfected Chi-
nese hamster ovary (CHO) cell clones are resistant to the
infection by picornavirus such as mengovirus (Chebath
et al., 1987). Mengovirus and EMCV are murine viruses,
members of the cardioviruses, one out of the six genera
that make up the Picornaviridae family. The mechanisms
of the antiviral activity of IFN-a against CVB belonging to
an other genera of this family has not been studied. In
response to IFN, a variety of IFN-inducible proteins with
different antiviral activities are produced, but the antiviral
protein(s) interfering with CVB replication is(are) not
known. The present study demonstrates in vitro that the
multiplication of CVB4, a positive-strand RNA virus, is
inhibited in MxA expressing cells.
RESULTS
Inhibition of CVB4 replication in MxA-transfected cells
MxA-transfected Vero cells (VA9) and pSV2-trans-
fected Vero cells (VN5) were tested for MxA expression
by indirect immunofluorescence and the MxA protein
was quantitated by using a method based on immuno-
chemiluminescence. MxA accumulated in the cytoplasm
of VA9 cells and showed a granular staining pattern (Fig.
1A). MxA was expressed in more than 98% of the cells as
judged by immunofluorescence analysis. No MxA stain-
FIG. 1. Expression of MxA in permanently transfected African green m
VA9). (A) Indirect immunofluorescent assay in VA9 cells. Arrow, MxA
Magnification, 31000. (B) Quantitation of MxA. VA9 cells and VN5 cell
ml buffer containing ascorbic acid in supernatant-free wells. Then, the M
The background value was 10 ng/ml. The results are representative oing was evidenced in VN5 cells. An enhanced MxA level
was detected in VA9 cells compared with VN5 cells. TheMxA level in VN5 did not differ from background values
obtained in various cell lines (Fig. 1B).
VA9, VN5, and HEp-2 cells were incubated in the
presence of CVB4 or VSV, both at m.o.i. 0.1 for 2 h 30
min. Then unadsorbed viruses were removed by wash-
ing and the cultures were continued. CVB-induced
cytopathic effects in VA9 and VN5 cells were assessed
by microscopic examination at various time points and
culture supernatants from CVB4, and VSV-infected
cells, harvested at 24-h postinfection, were subjected
to virus-yield reduction assays in HEp-2 cells. There
was no cytopathic effect of CVB4 in VA9 cells up to
72-h postinfection, whereas 25 and 100% of the mono-
layers were altered at 24- and 72-h postinfection in
VN5 cells (Fig. 2A). No CPE was observed in HEp-2
cells when they were cultured in the presence of
supernatant samples obtained from CVB4- or VSV-
exposed VA9 cells; the virus titers in supernatants
from these cultures were ,1 3 101 TCID50/ml. Oppo-
sitely, 2 3 104 and 3 3 105 TCID50/ml were detected in
upernatant samples of CVB4- and VSV-infected VN5
ell cultures, respectively (Fig. 2B). In contrast, the
eplication of HSV-1 was not affected by MxA; indeed,
he HSV-1-induced cytopathic effect was not different
n VA9 and VN5 cells. More than 25% of cells were
estroyed 24-h postinfection in both cases (data not
hown). The protein 29–59 OAS is one of the function-
lly important type I IFN-induced intracellular proteins
hich plays a major role in defense against virus
nfection, including picornavirus (Chebath et al., 1987).
herefore the levels of 29–59 OAS-induced 29–59 ade-
ylate in CVB4-infected VA9 and VN5 cells has been
valuated. Figure 3 shows that the 29–59 adenylate
evels were higher in VA9 and VN5 cells treated with
FN-a for 12 h compared with controls, whereas CVB4
kidney (Vero) cells constitutively expressing human MxA protein (clone
ve cell. The slides were observed with a fluorescence microscope.
essing only the neomycin resistance gene) were lysed by adding 200
quantitated by using a method based on immunochemiluminescence.
dependent experiments.onkey
-negati
s (exprinfection did not increase the 29–59 adenylate levels in
these cells.
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86 CHIEUX ET AL.Decreased synthesis of capsid protein and viral RNA
in MxA-transfected cells infected with CVB
VA9, VN5, and HEp-2 cells were incubated in the
presence of CVB4 at m.o.i. 0.1 for 2 h 30 min. Then,
unadsorbed virus was removed by washing and the
cultures were continued for 24 and 48 h. The presence of
the enterovirus structural protein VP1 (VP1) was studied
by using an indirect immunofluorescent assay (see Fig.
4). VP1 was not detected in cells 4-h postinfection,
whereas a positive signal appeared at 7-h postinfection
in cytoplasm of VN5 and HEp-2 cells, but not in the one
of VA9 cells. The proportion of VP-1-positive cells
reached 50% 24 h.p.i. for both VN5 and HEp-2 cells.
Oppositely, no VA9 cell was positive for VP1 at 24 h.p.i. At
48 h.p.i., more than 80% of CVB4-infected VN5 and HEp-2
cells accumulated VP1 in their cytoplasm, whereas no
VA9 was positive for FITC staining of VP1 at this time.
Mock-infected VN5, VA9, and HEp2 cells were negative
for indirect immunofluorescent assay. At each studied
time postinfection, the viability of VA9 cells was more
FIG. 2. Antiviral activity against coxsackie virus B4 (CVB4) and vesic-
lar stomatitis vesicular virus (VSV) in MxA-expressing cells (VA9) and
ontrol cells (VN5). (A) Cytopathic effect in VN5 and VA9 infected with
VB4, m.o.i.: 0.1 for 2 h 30 min at 37°C. Then the unadsorbed virus was
emoved by washing and the cultures were continued with fresh me-
ium. The cell monolayers were observed with an inverted microscope
nd the results were expressed as percentage of destruction. (B) Virus
iters of culture supernatants were determined at 24 h.p.i. for VSV and
t 48 h.p.i. for CVB4 by the TCID50 assay by using HEp-2 cells. The
esults are representative of two independent experiments.than 90% as tested by Trypan blue exclusion assay (data
not shown).
w
sTo determine whether the synthesis of CVB4 RNA
occurred in MxA-expressing cells, monolayers of trans-
fected Vero, control, and HEp-2 cells were exposed to
CVB4 at a m.o.i. of 1; then, accumulation of viral RNA was
monitored 4 and 24 h.p.i. by in situ hybridization (ISH)
see Fig. 5). At 4 h.p.i., 15% of CVB4-infected VN5 cells
ere positive, whereas no VA9 cell was revealed CVB4
NA positive. At 24 h.p.i., 40–50% of CVB4-infected VN5
ells were viral RNA positive, whereas no CVB4 RNA
ccumulation was observed in VA9 cells.
To further explore the CVB4 replication, the cells were
ashed extensively at 4°C to remove residual viruses,
hen plus- and minus-sense viral RNA strands were stud-
ed by RT-PCR (see Fig. 6). At 4 h.p.i., the detection of
lus-sense viral RNA strands was positive in VN5 and
Ep-2 cells and weakly positive in VA9 cells, whereas
he detection of minus-sense viral RNA strands was
ositive in HEp-2 cells only (data not shown). At 24 h.p.i,
ignificant accumulation of positive- and negative-strand
iral RNA occurred in infected HEp-2 and VN5 cells,
hereas the signal for the detection of positive-strand
iral RNA was weak in VA9 cells and that the signal for
he detection of negative-strand viral RNA was absent in
hese cells.
DISCUSSION
The antiviral activity of Mx proteins has been reported
gainst negative- and positive-strand RNA viruses (Frese
t al., 1995, 1996; Staeheli and Pavlovic, 1991;
chwemmle et al., 1995), whereas it has been reported
hat MxA had no effect on Mengo virus or ECM virus
elonging to the Picornaviridae family (Landis et al.,
998). In the present study, the antiviral spectrum of MxA
gainst CVB4, a member of the enterovirus group in the
icornaviridae family, has been investigated.
FIG. 3. Quantitation of 29–59 adenylate generated in MxA-expressing
ero cells (VA9) and control cells (VN5). Infected were 0.5 3 105 cells
ith CVB4 (m.o.i. 0.1 for 2 h 30 min at 37°C; then the unadsorbed virus
as removed by washing and the cultures were continued); mock-
nfected; or treated with 100 IU/ml IFN-a2b. The cells were cultured for
12 h; then they were washed and the cells were lysed by adding 200 ml
uffer containing ascorbic acid in supernatant-free wells for 30 min at
oom temperature. Finally, the 29–59 adenylate contained in 50 ml lysate
as quantitated by using a radioimmunoassay. The results are repre-
entative of two independent experiments.
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87MxA PROTEIN AND COXSACKIEVIRUS B4There are several noteworthy considerations for the
systems used in the study. Vero cells have been chosen
because they are sensitive to various viruses causing a
cytopathic effect in these cells. Transfected Vero cells
expressing MxA allowed the demonstration that MxA, an
IFN type I-induced molecule, is a powerful antiviral pro-
tein able to inhibit diverse groups of viruses (Pavlovic et
al., 1992; Frese et al., 1995, 1996). Although the anti-CVB
ctivity of IFN-a is known, the mechanism by which
IFN-a inhibits CVB replication remains unclear. This is
he first study focusing on the effects of MxA on CVB
eplication. The rationale for choosing CVB4E2 in our
ystem was to examine the antiviral spectrum of MxA
gainst a CVB4 strain, isolated from a patient with insu-
in-dependent diabetes mellitus (IDDM) (Gerling et al.,
FIG. 4. Detection of enterovirus capsid protein VP1 in MxA-expressin
for 2 h 30 min at 37°C; then, the unadsorbed virus was removed by wa
105) were indirectly stained for VP1 with FITC-conjugated antibodies
CVB4-infected cells at different intervals after infection. (B) and (C) VN5
with a fluorescence microscope. Magnification, 31000. Arrow, VP1-po
FIG. 5. In situ hybridization for sense-strand viral RNA of CVB4. HEp-2
Then the unadsorbed virus was removed by washing and the cultures
trypsinized and then fixed before being hybridized with a biotinylated probe. (
(magnification, 31000). (B) Percentage of sense-strand viral RNA-positive cel991). EV RNA with strong homology with CVB4 has been
etected in the peripheral blood of patients with IDDM,
nd CVB4 infection was associated with activation of
FN-a synthesis in these patients (Chehadeh et al.,
000a). Recently we brought evidence that a persistent
nfection of human pancreatic islets by CVB4, especially
VB4E2, is associated with interferon-a synthesis in b
cells (Chehadeh et al., 2000b). Thus, it appears that CVB4
ay play an important role in human pathology, espe-
ially IDDM, and that IFN-a is produced in the course of
CVB4 infection; therefore an understanding of molecular
basis of the interaction between that virus and IFN-a
may provide insight into the mechanisms of the patho-
genesis of CVB4-induced diseases.
Vero cells expressing MxA were protected from the
(VA9) and control cells (VN5). Cells were infected with CVB4, m.o.i. 0.1
nd the cultures were continued with fresh medium at 37°C. Cells (2 3
unterstained with Evan blue. (A) Percentage of VP1 positive cells in
9 cells, respectively, at 24 h after infection. The slides were observed
ell.
and VA9 cells were infected with CVB4; m.o.i., 1 for 2 h 30 min at 37°C.
ontinued with fresh medium at 37°C. At 4 and 24 h.p.i., the cells wereg cells
shing a
and co, VN5,
were cA) Cells stained for viral RNA at 4 h.p.i. Arrow, cell with positive signal
ls at 4 and 24 h after infection.
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88 CHIEUX ET AL.cytopathic effect of CVB4, whereas cytopathic killing of
control cultures was completed within 72 h.p.i. A very low
level of infectious particles has been detected in the
supernatant of CVB4-exposed MxA-expressing cells
compared with control cells. The CVB replication at the
molecular level was investigated. Immunofluorescence
analysis revealed that no VA9 cell expressed VP1 capsid
protein, whereas more than 80% of VN5 cells were pos-
itive for VP1 at 48 h.p.i. A drastic reduction of viral RNA
synthesis was observed in CVB4-exposed VA9 cells
compared with VN5 cells. Together these results show
that CVB replication is strongly inhibited in MxA-express-
ing cells.
In VA9 cells the cytopathic effect of CVB4 was inhib-
ited, whereas the cytopathic effect of HSV-1 was not
different in VA9 and VN5 cells as expected since it has
been already reported that MxA-expressing cells were
not protected against the cytopathic effect of HSV1 (Lan-
dis et al., 1998). In contrast with control cells, MxA-
expressing cells were resistant to infection with VSV, a
MxA-sensitive virus (Pavlovic et al., 1990). These results
show that the antiviral activity observed in VA9 cells
against CVB4 was not due to antiviral physiological pa-
rameters of these cells and suggest that MxA exerts an
intrinsic antiviral activity against CVB4.
Vero cells are devoid of type I IFN genes because of a
chromosomal deletion in their genome (Diaz et al., 1988);
thus the role of endogenous type I IFN-a in the anti-CVB
ctivity of VA9 cells can be excluded. It has been re-
orted that viruses can directly stimulate the synthesis of
ntiviral protein by cells independently of IFN-a/b (Ronni
et al., 1993; Baca et al., 1994). VA9 and VN5 cells synthe-
tized 29–59 adenylate in response to IFN-a, whereas the
evels of 29–59 adenylate were not higher in CVB-infected
FIG. 6. Agarose gel electrophoresis of amplicons specific to positive-
sense viral RNA (A) and negative-sense viral RNA (B) strands of en-
terovirus genome. HEp-2, VN5, and VA9 cells were infected with CVB4;
m.o.i., 1 for 2 h 30 min at 37°C. Then the unadsorbed virus was
removed by washing and the cultures were continued with fresh me-
dium at 37°C. Strand-specific RT-PCR was carried out on total RNA
taken from CVB4-infected and mock-infected cells CVB4 at 24 h.p.i.
Lane 1 corresponds to 100-bp DNA molecular size ladder. Lanes 2 and
4 correspond to mock-infected VN5 and HEp-2 cells, respectively.
Lanes 3 and 7 correspond to CVB4-infected VN5 and HEp-2 cells,
respectively. Lanes 5 and 6 correspond to CVB4-infected VA9 cells
(duplicates). Expression of b-actin mRNA was detected in all samples
C). Representative experiments of two identically performed experi-
ents are shown.A9 and VN5 cells than in mock-infected cells. Together
hese data argue against a major role of CVB4-induced
1
i9–59 adenylate in the anti-CVB effect observed in MxA-
xpressing cells.
CVB4 shares susceptibility to MxA with SFV, another
ositive-strand RNA virus (Landis et al., 1998), and cer-
ain negative-strand RNA viruses: VSV, influenza virus,
unyaviruses, and Thogoto virus (Frese et al., 1995, 1996;
Pavlovic et al., 1992; Staeheli and Pavlovic, 1991).
The washing procedure of cells at 4°C before total
RNA extraction eliminates the residual extracellular viral
particles (Chehadeh et al., 2000b). The detection of a low
level of positive-strand RNA, probably related to the pres-
ence of CVB genome in the cytoplasm of the cells,
associated with the lack of minus-strand RNA at 24 h.p.i.
in CVB4-exposed VA9 cells by using RT-PCR suggests
that the viral replication in MxA-expressing Vero cells
was inhibited at an early step after the entry of viral
genome into the cells.
The precise mechanism interfering with CVB replica-
tion remains to be elucidated; however, the abortion of
viral infection at an early step of infection in the case of
CVB is reminiscent of other reports. In the case of SFV, a
positive-strand RNA virus, the antiviral effect of MxA is
related to a block occurring early in the replicative cycle,
and it has been demonstrated that viral components
other than structural proteins are targets for MxA effect
(Landis et al., 1998). MxA protein selectively blocks the
multiplication of negative-strand RNA viruses, VSV, mem-
bers of the Bunyaviridae family, and Thogoto virus, by
interacting with an early step of virus replication (Frese
et al., 1995, 1996). MxA protein selectively blocks the viral
multiplication at the level of primary transcription for VSV
(Schwemmle et al., 1995; Staeheli and Pavlovic, 1991)
and blocks the transport of Thogoto virus nucleocapsids
into the nucleus by binding to the nucleoprotein compo-
nent, thereby preventing transcription of the viral ge-
nome (Kochs and Haller, 1999). In contrast, MxA inhibits
a step later than primary transcription for influenza virus
(Pavlovic et al., 1992).
These studies demonstrate that the antiviral activity of
MxA against positive-strand RNA viruses is not restricted
to SFV, one member of the Togaviridae family, but ex-
tends to CVB4, one member of the enterovirus group in
the Picornaviridae family. There are differences between
various genera of the Picornaviridae family which may
explain why MxA is effective against CVB4 (enterovirus
genera) and not other picornaviruses such as mengovi-
rus and EMC (cardiovirus genera) (Landis et al., 1998).
Moreover, it has already been reported that negative-
strand RNA viruses in the same family do not have the
same susceptibility to MxA (Frese et al., 1995). The cur-
rent study shows that 29–59 adenylate is not the sole
system that can serve the antipicornavirus effects of
IFN-a. It has been suggested that the antiviral activity of
xA may be modulated by host factors (Frese et al.,
996). It will be of interest to investigate the role of MxA
n the infection of human host cells with CVB4 for a better
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89MxA PROTEIN AND COXSACKIEVIRUS B4knowledge of mechanisms of anti-CVB defenses and
pathogenesis of CVB4-induced diseases.
MATERIALS AND METHODS
Viruses
Coxsackie Virus B4 (CVB4) is the CVB4E2 strain (pro-
vided by Dr. Ji-Won Yoon, Calgary, Canada) grown in
Hep-2 cells (Biowhittaker, Verviers, Belgium) in Eagle’s
minimum essential medium (MEM; GIBCO BRL, Paisley,
Scotland) supplemented with 10% FCS and 1% L-glu-
amine. Supernatants were collected 3 days postinfec-
ion and then clarified at 1000 rpm for 10 min. Virus titers
ere determined by plaque-formation assay on HEp-2
ells and aliquots of virus preparations were then stored
rozen at 280°C.
Vesicular stomatitis virus (kindly provided by P. Lebon,
aris, France) was grown in Vero cells (Biowhittaker) in
agle’s MEM (GIBCO BRL) supplemented with 10% FCS
nd 1% L-glutamine. Supernatants were collected 3 days
postinfection and then clarified at 1000 rpm for 10 min.
Virus titers were determined by plaque-formation assay
on HEp-2 cells and aliquots of virus preparations were
then stored frozen at 280°C.
Herpes simplex virus type-1 (laboratory strain) was
cultivated in a Vero cell line (ATCC, Rockville, MD) in
MEM supplemented with 5% FCS and 1% L-glutamine.
After 48 h incubation at 37°C in 5% humidified CO2
atmosphere, supernatants were collected and clarified at
1000 rpm for 10 min. HSV-1 titers were assayed by
plaque formation on Vero cells and virus preparations
were stored at 280°C.
Cell
Permanently transfected African green monkey kidney
(Vero) cells constitutively expressing human MxA protein
(clone VA9) and control cells expressing only the neomy-
cin resistance gene (clone VN5) were grown in Dul-
becco’s modified Eagle’s medium containing 10% fetal
calf serum (GIBCO-BRL, Berlin, Germany), 1% of L-glu-
tamine (Eurobio, Les Ulis, France) and 1% of nonessen-
tial amino acids (GIBCO-BRL, Paisley, Scotland) and 0.5
mg/ml neomycin-G418 (GIBCO-BRL) (Frese et al., 1996).
Virus yield reduction assay
Confluent cell monolayers were infected as described.
Culture supernatants were collected 24 h.p.i. and virus
yields were determined on HEp-2 cells by TCID50
method 24 h.p.i. for VSV and 48 h for CVB4.
Immunofluorescence (IF)
Detection of MxA protein and enterovirus VP1. The
cells were carefully washed with MEM. The cells were
then trypsined, removed from the wells by pipetting, and
washed twice before 2 3 105 cells were cytocentrifuged
w
tnto clean glass slides. The slides were air-dried and
ixed in a solution of 4% paraformaldehyde (PFA; Sigma)
or 20 min at 4°C. The slides were washed twice in PBS
nd permeabilized with cold acetone/methanol (1 v/2 v)
or 10 min at 20°C. After washing twice in PBS, the slides
ere incubated with 5% normal rabbit serum for 1 h at
oom temperature (RT) in a humidified chamber, washed
wice in PBS, and incubated for 1 h at RT either with
onoclonal anti-MxA at 1 mg/spot. or with monoclonal
nti-enterovirus VP1 (DAKO, Carpinteria, USA) at a dilu-
ion of 1:20. Following three washes in PBS, the slides
ere stained with 1:100 dilution of FITC-conjugated anti-
ouse IgG antibodies (Sigma), counterstained with
vans blue (Sigma), and washed 3 times in PBS. Irrele-
ant mouse IgG antibodies (Coulter Immunotech) were
sed as controls. The slides were then mounted with
ermafluor (Coulter Immunotech), and positive cells
ere enumerated in a fluorescence microscope (Leitz
iaplan, Wetzlar, Germany).
uantitation of MxA protein
Monolayers of both clones VA9 and VN5 have been
ncubated at 37°C in a 5% CO2 humidified atmosphere
or 24 h. Then, the culture medium was removed and
he cells (0.5 3 105) were washed twice with PBS prior
o be lysed by 200 ml buffer containing ascorbic acid
ACS 180, Bayer Diagnostics, Villeneuve D’Ascq,
rance) for 30 min at room temperature (Chieux et al.,
998). Briefly, 200 ml of lysate, standards, and controls
ere incubated simultaneously in plastic tubes with
00 ml of Lite Reagent (N-hydroxysuccinimide-acti-
vated dimethyl-acridinium-ester-labeled detector anti-
body) and 200 ml of solid phase (Paramagnetic-parti-
cles-conjugated antibody) (Bayer Diagnostics Corp.,
Alameda, CA). The tubes were then shaken by using a
multi-tube vortexer (Model 4010, Bayer Diagnostics)
for 3 min at room temperature. Then, these mixtures
were incubated 30 min at 37°C. After incubation, the
solid phase-bound immune complex was separated
with a magnetized separator rack, Magic Rack (Bayer
Diagnostics) for 3 min at room temperature. The sep-
arated pellets were then resuspended in 1 ml of dis-
tilled water using the multi-tube vortexer. The unbound
antigen or antibody was discarded by decanting the
rack. The separated pellets were then washed once
more with 1 ml of distilled water as described above.
Then, the separated pellets were resuspended in 100
ml of distilled water. The relative luminescence units
RLUs) were counted by using a MLA-I luminometer
Bayer Diagnostics). The RLUs were converted in
anograms per milliliters by using a master curve. The
ackground of MxA quantitation in various cell lines
ith negative MxA detection by IF that do not synthe-
ize MxA represented 9 6 0.3 ng/ml MxA equivalent.
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90 CHIEUX ET AL.Quantitation of 29–59 OAS
Cell preparation. Monolayers of VA9 and VN5 cells
ave been incubated in the absence or presence of
VB4, m.o.i. 0.1 for 2 h 30 min at 37°C in a 5% CO2
humidified atmosphere. Then, the medium was removed
and the cells were washed 5 times with culture medium.
After that, the cultures were continued for 12 h in the
same conditions. Finally, the culture medium was re-
moved and the cells were washed twice with PBS prior
to be lysed by 200 ml buffer containing ascorbic acid
ACS 180, Bayer Diagnostics) for 30 min at room temper-
ture. Since 29–59 OAS is an IFN-a/b-induced antiviral
rotein, VA9 and VN5 cells were incubated in the pres-
nce of recombinant IFN-a2b 100 IU/ml (Introna, Shering-
lough, Germany) for 12 h; then they were lysed and
ested for their 29–59 OAS concentration.
The intracellular concentration of 29–59 OAS contained
n 50 ml lysate have been measured by radioimmunoas-
say with 125I as the tracer and a second antibody used as
he bound/free (B/F) separating agent (2–5A Kit I-AP75,
iken Chemical Co. Ltd., Tokyo, Japan). Briefly, first the
9–59 OAS in the sample is adsorbed and activated by
sing poly(I) poly(C) agarose; then 29–59 adenylate is
produced by using adenosine triphosphate (ATP) as the
substrate. Next, a mixture of 125I-labeled 29–59 adenylate,
nti-29–59 adenylate serum, and second antibody is
dded. After 1 h incubation at 37°C, the mixture is cen-
rifugally separated, and the B/F separation is performed
y suction. Finally, the radioactivity of the precipitate is
easured with a gamma counter (Diastar Packard, Neth-
rland). The binding rate with respect to the initially
dded 125I-labeled 29–59 adenylate quantity is calculated,
nd the quantity of 29–59 adenylate produced by the 29–59
AS in the sample is obtained from the standard curve
hich was made at the same time.
T-PCR experiments
RNA extraction. Native RNA was extracted from cells
y the acid guanidinium thiocyanate phenol chloroform
xtraction procedure using a commercial system
RNAgents Total RNA Isolation System, Promega, Madi-
on, WI). Extracted RNA was then dissolved in 50 ml of
diethylpyrocarbonate (DEPC)-treated water (Aldrich,
Saint Quentin Fallavier, France) and used in the RT-PCR
assays.
Oligonucleotide primers. The sequences of the entero-
virus-specific primers were selected in the 59 untrans-
lated region of the viral genome, since this region is
highly conserved among all enterovirus strains. Up-
stream primer, 59-CAAGCACTTCTGTTTCCCCGG-39, and
downstream primer, 59-ATTGTCACCATAAGCAGCCA-39,
generate a 435-bp fragment. These primers were syn-
thesized by Eurogentec (Eurogentec Bel SA, Seraing,
Belgium) and were previously described by Leparc et al.
(1994).Beta-actin (b-actin) primers were synthesized by Eu-
rogentec; upstream primer: 5-9ATCATGTTTGAGACCTC-
CAA-39; downstream primer: 59-CATCTCTTGCTC-
GAAGTCCA-39. The amplified PCR fragment size is 318
bp.
RT-PCR reaction for plus-sense and minus-sense EV
RNA strand detection. In the course of CVB replication,
parental plus-sense RNA strand is transcribed into a
minus-sense RNA strand which serves as a template for
transcription into progeny plus-sense RNA strand. Down-
stream or upstream EV primer at 0.4 mM was used as
emplate in synthesis of complementary cDNA for 0.1 mg
lus- or minus-sense EV RNA strand, respectively, in a
otal volume of 20 ml, using the enhanced avian RT-PCR
kit (Sigma) according to the manufacturer’s instructions.
The transcription reaction was carried out at 50°C for 50
min and was stopped by heating the samples for 5 min
at 95°C. The PCR reaction was carried out using 5 ml of
DNA samples and 0.4 mM of each primer, in a total
olume of 50 ml. For all specimens, b-actin mRNA was
mplified using specific primers in a RT-PCR reaction. All
CR reactions were carried out using a Perkin–Elmer
pplied GeneAmp PCR System 2400.
Detection of PCR products. The amplified RT-PCR
roducts were analyzed on 2% agarose gel containing
.5 mg/ml of ethidium bromide (Sigma) and visualized
using Gel Doc 2000system (Bio-Rad SA, Ivry-sur-seine,
France). Image processing and analysis operations of
DNA bands were performed using Quantity One software
(Bio-Rad SA). A 100-bp DNA Ladder (GIBCO-BRL) was
used as a molecular-weight marker.
In situ hybridization (ISH)
Enterovirus RNA-specific ISH was performed on cyto-
spin preparations using nuclease-free polylysine-coated
glass slides (Poly Labo, Paris, France) at 2 3 105 cells/
spot. VA9, VN5, and HEp-2 cells were fixed in acetone for
20 min at RT and then immersed in Target retrieval
solution (DAKO) at 95°C for 40 min (Chehadeh et al.,
2000b). Afterward, slides were washed twice in distilled
water and treated for 5 min at RT with proteinase K
(DAKO) diluted 1:5000 in 50 mM Tris–HCl buffer, pH 7.6
(Merck). Slides were washed and immersed in 0.3% H2O2
in methanol at RT overnight. After washing, slides were
hybridized in mRNA ISH solution (DAKO) containing 1
ng/ml of biotinylated probe (5-(biotin)AAC-ACG-GAC-
CC-CAA-AGT-A-3) selected in the 59 untranslated re-
ion of the enteroviral genome. The probe was synthe-
ized and labeled by Eurogentec. For each slide, 15 ml of
hybridization mixture was applied before nuclease-free
Hybrislips (Poly Labo) were mounted, and hybridization
was performed at 50°C for 90 min in a humidified cham-
ber. Slides were then washed in Tris-buffered saline
containing Tween–TBST (DAKO) for 20 min at RT. The
hybridized probe was revealed by using Genpoint sys-
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91MxA PROTEIN AND COXSACKIEVIRUS B4tem (DAKO), consisting of an amplification of biotin sig-
nal by initial binding of peroxidase-conjugated streptavi-
din to the biotinylated probe followed by application of
biotinyl-tyramide. The additional biotin is then used to
capture more peroxidase-conjugated streptavidin. The
signal is finally developed by adding the diaminobenzi-
dine (DAB) dye to produce a dark brown precipitate at
the site of hybridization. The sensitivity of ISH test was
determined on HEp-2 cells infected with CVB4 (18% of
HEp2 cells were labeled when infected at a m.o.i. of 1
PFU, and then hybridized 4 h after infection). To deter-
mine the specificity of signal, cells were subjected to
RNase A (Boehringer Mannheim, Meylan, France) treat-
ment at 100 mg/ml for 2 h at 37°C before hybridization.
RNase was heated at 100°C for 10 min and then allowed
to cool to RT before use to abolish residual DNase
activity.
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